Sec Form 3 Filing - Ben Arye Barak @ NovoCure Ltd - 2022-04-14

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Ben Arye Barak 2. Issuer Name and Ticker or Trading Symbol NovoCure Ltd [ NVCR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) General Counsel (Last) (First) (Middle) C/O NOVOCURE INC.,, SUITE 300 3. Date of Earliest Transaction (MM/DD/YY) 04/14/2022 (Street) MALVERN, PA19355 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 4,223 D Restricted Share Units 299( 1 ) D Restricted Share Units 7,605( 2 ) D Restricted Share Units 870( 3 ) D Restricted Share Units 464( 4 ) D Restricted Share Units 2,016( 5 ) D Restricted Share Units 1,381( 6 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Options to Buy Ordinary Shares $ 83.3 ( 7 ) 07/30/2029 Ordinary Shares 780 D Options to Buy Ordinary Shares $ 21.15 ( 8 ) 02/26/2028 Ordinary Shares 2,851 D Options to Buy Ordinary Shares $ 69.37 ( 9 ) 03/02/2030 Ordinary Shares 7,990 D Options to Buy Ordinary Shares $ 47.04 ( 10 ) 03/21/2029 Ordinary Shares 2,432 D Options to Buy Ordinary Shares $ 87.66 ( 11 ) 03/31/2032 Ordinary Shares 13,131 D Options to Buy Ordinary Shares $ 107.73 ( 12 ) 11/01/2031 Ordinary Shares 831 D Options to Buy Ordinary Shares $ 80.59 ( 13 ) 02/29/2032 Ordinary Shares 3,532 D Options to Buy Ordinary Shares $ 153.09 ( 14 ) 03/01/2031 Ordinary Shares 2,401 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Ben Arye Barak C/O NOVOCURE INC., SUITE 300 MALVERN, PA19355 General Counsel Signatures By: /s/ Steven Robbins, Attorney in Fact for Barak Ben Arye 04/14/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents restricted share units that are scheduled to vest on July 30, 2022, subject to the reporting person's continued employment through such dates. ( 2 )Represents restricted share units that are scheduled to vest on April 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. ( 3 )Represents restricted share units that are scheduled to vest on March 2, 2023 and 2024, subject to the reporting person's continued employment through such dates. ( 4 )Represents restricted share units that are scheduled to vest on November 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. ( 5 )Represents restricted share units that are scheduled to vest on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. ( 6 )Represents restricted share units that are scheduled to vest on March 3, 2023, subject to the reporting person's continued employment through such dates. ( 7 )Options to buy 780 ordinary shares will vest in equal installments on each of July 30, 2022 and 2023, subject to the reporting person's continued employment through such dates. ( 8 )Currently exercisable. ( 9 )Options to buy 7,990 ordinary shares, 3,996 shares of which are currently exercisable and the remainder vest in equal installments on each of March 3, 2023 and 2024, subject to the reporting person's continued employment through such dates. ( 10 )Options to buy 2,432 ordinary shares, 1,216 shares of which are currently exercisable and the remainder vest on March 22, 2023, subject to the reporting person's continued employment through such dates. ( 11 )Options to buy 13,131 ordinary shares will vest in equal installments on each of April 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. ( 12 )Options to buy 831 ordinary shares will vest in equal installments on each of November 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. ( 13 )Options to buy 3,532 ordinary shares will vest in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. ( 14 )Options to buy 2,401 ordinary shares, 601 shares of which are currently exercisable and the remainder vest in equal installments on each of March 2, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.